Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study

Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study

Abstract Background Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC)....

Full description

Saved in:
Bibliographic Details
Main Authors: Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri, Mark Nathan
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Abemaciclib
Medical chart review
Metastatic breast cancer
Observational
Real-world
Retrospective
Online Access:https://doi.org/10.1186/s12885-025-14526-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14526-w

Similar Items